U

Universitätsklinikum Freiburg | Klinik fur Dermatologie und Venerologie

Research site
(Unclaimed)
Location
Haupstraße 7, Freiburg, Baden-Württemberg, Germany

Site insights

Top conditions

Top treatments

Darolutamide
Etavopivat
5-Fluorouracil
Eteplirsen
BC 007
Octreotide
Leucovorin
Trabectedin
Aflibercept
Atezolizumab

Parent organization

This site is a part of Universitätsklinikum Freiburg

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 25 total trials

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung dise...

Enrolling
Chronic Lung Disease of Prematurity
Intraventricular Hemorrhage
Drug: OHB-607

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: HZN-825 BID
Drug: HZN-825 QD

The primary efficacy objective:To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.The secondary effic...

Enrolling
Idiopathic Inflammatory Myositis
Drug: Placebo
Drug: Daxdilimab

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Tirzepatide
Drug: Cagrilintide

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This study will be comprised of 2 parts: Part 1 (dose escalation) will be conducted to evaluate the safety and tolerability of 2 doses (100 milligram...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting
Lupus Nephritis
Drug: Obinutuzumab
Drug: MMF

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic scl...

Enrolling
Systemic Sclerosis
Drug: Placebo
Drug: RO7303509

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Diagnostic Test: Fluorescein

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulve...

Enrolling
HER2-negative Metastatic Breast Cancer
Hormone Receptor-positive Metastatic Breast Cancer
Drug: Abemaciclib + Aromatase Inhibitor
Drug: Abemaciclib + Fulvestrant

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monothe...

Enrolling
Low-grade Glioma
Drug: Chemotherapeutic Agent
Drug: Tovorafenib

This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI...

Enrolling
Myocardial Infarction
Drug: BI 765845
Drug: Placebo matching BI 765845

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

This study is an interventional, randomized, multinational, multicenter, double-blind, phase 2 study with a follow-up period of circa 12 months.The i...

Active, not recruiting
Long Covid
Drug: BC 007 or matching placebo

Trial sponsors

Amgen logo
Bayer logo
Boehringer Ingelheim logo
Genentech logo
Aesculap logo
B
Boston Scientific logo
C
D
Forma Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems